-
1.发明申请COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS 有权化合物及其在各种AMYLOID BETA PEPTIDE ALLOFORMS的调节水平中的应用公开(公告)号：US20130165416A1
公开(公告)日：2013-06-27
申请号：US13806692
申请日：2011-06-24
IPC分类号： C07D417/14 , C07F9/6558
CPC分类号： C07D417/14 , C07F9/65583
摘要： The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D) (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
摘要翻译： 本发明提供具有对应于式（I）：（A） - （B） - （C） - （D）（I）的结构或其药学上可接受的盐或前药的结构的新化合物及其使用方法。
-
2.发明授权Monoclonal antibody produced against native .beta.amyloid precursor protein 失效针对天然β淀粉样蛋白前体蛋白产生单克隆抗体
公开(公告)号：US5427931A
公开(公告)日：1995-06-27
申请号：US56423
申请日：1993-04-27
IPC分类号： C12P21/08 , G01N33/573 , G01N33/68 , G01N33/86 , A61K39/395
CPC分类号： G01N33/6896 , G01N33/573 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of .beta.APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of .beta.APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of .beta.APP in CSF, down to a total concentration of the secreted forms of .beta.APP of 3.75 .mu.g/ml or lower.
摘要翻译： 公开了单克隆抗体和产生抗体的杂交瘤。 针对beta APP的天然分泌形式的抗原产生抗体。 抗体的特征在于，抗体特异性结合已经生长了神经母细胞瘤细胞的培养基中的至少一种蛋白质。 该蛋白质在非还原性聚丙烯酰胺凝胶电泳中共同迁移，并从人成纤维细胞培养物中分离出PN-2。 抗体的其他特征是抗体特异性结合PN-2和分泌形式的缺乏Kunitz型抑制剂结构域的βAPP，抗体选择性地结合神经炎斑块，并且抗体足够敏感以检测分泌形式 βAPP在CSF中，分泌形式的APP的总浓度为3.75μg/ ml或更低。
-
公开(公告)号：US5270165A
公开(公告)日：1993-12-14
申请号：US779070
申请日：1991-10-15
IPC分类号： A61K39/395 , C12N5/10 , C12N9/99 , C12N15/02 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/645 , C12R1/91 , G01N33/53 , G01N33/573 , G01N33/577 , G01N33/68 , G01N33/86
CPC分类号： G01N33/573 , G01N33/6896 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample fromNOTICE OF GOVERNMENT SUPPORTThis invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.
摘要翻译： 公开了一种在哺乳动物中诊断淀粉样蛋白的脑血管沉积的疾病，包括阿尔茨海默氏病，淀粉样变性 - 荷兰型和其他淀粉样变性的遗传性脑出血，其中获得脑脊液样品，对单克隆抗体的免疫反应性水平 测量样品中针对天然PN-2 /βAPP或其他淀粉样蛋白前体蛋白产生的抗体，并将该测量水平与来自正常受试者的样品中针对该抗体的免疫反应性水平进行比较。 来自哺乳动物样本的较低水平表明该疾病的可能性。
-
4.发明授权Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms 有权化合物及其在调节各种淀粉样β肽异构体水平中的用途公开(公告)号：US09403815B2
公开(公告)日：2016-08-02
申请号：US13806692
申请日：2011-06-24
IPC分类号： C07D417/14 , C07F9/6558
CPC分类号： C07D417/14 , C07F9/65583
摘要： The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D) (I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
摘要翻译： 本发明提供具有对应于式（I）：（A） - （B） - （C） - （D）（I）的结构或其药学上可接受的盐或前药的结构的新化合物及其使用方法。
-
5.发明授权Monoclonal antibodies specific for protease nexin-1 and puriciation of protease nexin-1 using monoclonal antibodies 失效使用单克隆抗体对蛋白酶nexin-1特异的单克隆抗体和蛋白酶nexin-1的纯化
公开(公告)号：US5134076A
公开(公告)日：1992-07-28
申请号：US249787
申请日：1988-09-27
CPC分类号： C07K14/8121 , C07K16/38 , A61K38/00
摘要： Monoclonal antibodies having a specificity for protease nexin-1 are described. Preferably an antibody has specificity to the reactive protease-binding site. The antibody is used in the affinity purification of PN-1 to produce large quantities of substantially pure PN-1, free of other biologically active molecules. Over a 2000-fold purification of a crude preparation of PN-1 may be obtained. The affinity-purified PN-1 is suitable for use in pharmacological preparations used in the treatment of neurological disease associated with serine protease-mediated inhibition of regenerative processes.
摘要翻译： 描述了对蛋白酶nexin-1具有特异性的单克隆抗体。 优选地，抗体对反应性蛋白酶结合位点具有特异性。 该抗体用于亲和纯化PN-1以产生大量基本上纯的PN-1，其不含其他生物活性分子。 可以获得2000倍以上的PN-1粗制品的纯化。 亲和纯化的PN-1适用于用于治疗与丝氨酸蛋白酶介导的再生过程抑制相关的神经疾病的药理学制剂。
-
公开(公告)号：US10472346B2
公开(公告)日：2019-11-12
申请号：US15522969
申请日：2015-10-30
申请人： The General Hospital Coporation , The Regents of the University of California , Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr
发明人： Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr , Kevin D. Rynearson
IPC分类号： C07D401/14 , C07D413/14 , C07D487/04 , A61P25/28
摘要： Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
-
公开(公告)号：US5600565A
公开(公告)日：1997-02-04
申请号：US363197
申请日：1994-12-22
CPC分类号： G06Q10/08
摘要： Each item a system or order group carries a label having, in addition to a predetermined primary code denoting its item type, another, secondary, code representing a random identifier for that individual item. When a system or order group is to be packaged, a worker selects each item according to a list, scans its label, and physically places the item with the order group. The predetermined primary and random secondary codes are compared with those of previous items in the same order group. A complete match with the codes of another item in the same group causes the item to be rejected.
摘要翻译： 除了表示其项目类型的预定主要代码之外，系统或订单组的每个项目还包含代表该单独项目的随机标识符的另一个次要代码。 当要打包系统或订单组时，工作人员将根据列表选择每个项目，扫描其标签，并将物料与订单组物理放置。 将预定的主次序和随机二次码与相同次序组中的先前项相比较。 与同一组中的其他项目的代码完全匹配会导致该项目被拒绝。
-
公开(公告)号：US5213962A
公开(公告)日：1993-05-25
申请号：US924417
申请日：1992-07-30
IPC分类号： C12P21/08 , G01N33/573 , G01N33/68 , G01N33/86
CPC分类号： G01N33/6896 , G01N33/573 , G01N33/86 , G01N2333/4709 , G01N2800/2821
摘要： Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed. These uses include the treatment and prevention of amyloid plaques in Alzheimer's disease and Down's Syndrome
摘要翻译： 公开了蛋白酶Nexin-2和β淀粉样蛋白前体蛋白的免疫纯化。 还公开了检测蛋白酶Nexin-2的方法以及这些方法在诊断阿尔茨海默病和其他病症中的用途。 此外，公开了包括蛋白酶Nexin-2或其修饰形式的药物制剂。 还公开了药物制剂的医疗用途。 这些用途包括治疗和预防阿尔茨海默病和唐氏综合征中的淀粉样斑块
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.019 秒)